This product review focusses on the use of clindamycin 1%/tretinoin 0.025% fixed-dose combination therapy for acne vulgaris. It discusses the evidence in support of the use of this topical treatment, its dosage, interactions, safety, and efficacy and tolerability demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Dr Jo-Ann See, a dermatologist in private practice in Sydney, Australia.
Please login below to download this issue (PDF)